Gynecologic Cancers Research Program

妇科癌症研究计划

基本信息

批准号：
10177891
负责人：
DORIS Mangiaracina BENBROOK
金额：
$ 5.46万
依托单位：
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-05-01 至 2023-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10177891
关键词：
Address Award Biological Specimen Banks Cancer Center Cancer Center Support Grant Cancer Control Cancer Patient Cancer Research Project Catchment Area Clinical Clinical Oncology Clinical Trials Collaborations Development Direct Costs Doctor of Philosophy Enrollment Equilibrium Funding Goals Grant Gynecologic Oncology Health Services Accessibility Industry Institution Leadership Malignant Female Reproductive System Neoplasm Malignant Neoplasms Molecular Oklahoma Outcome Patient-Focused Outcomes Peer Review Phase Publications Publishing Randomized Randomized Clinical Trials Reporting Research Resistance Woman base cancer prevention cancer therapy carcinogenesis college design improved inter-institutional investigator-initiated trial member multidisciplinary novel pre-clinical programs randomized trial response standard of care translational cancer research treatment trial

项目摘要

GYNECOLOGIC CANCERS PROGRAM – ABSTRACT The goal of the Gynecologic Cancers (GC) program at the Stephenson Cancer Center (SCC) is to raise the standard of care and improve clinical outcomes for all women with gynecologic malignancies, with an emphasis on addressing problems relevant to Oklahoma, the SCC catchment area. Program members accomplish this goal by conducting transdisciplinary, team-based research that advances discovery of molecular mechanisms into early- and late-phase randomized trials. The Specific Aims for the GC program are: (1) to discover and interrogate molecular mechanisms central to carcinogenesis; (2) to investigate mechanisms underlying cancer therapy response and resistance; and (3) to design and conduct early- and late-phase randomized clinical trials that advance novel discoveries and improve patient outcomes in the catchment area and nation. Highlights of the GC program include: 1) highly interactive basic discovery and clinical members focused on gynecologic cancers; 2) Specific Aims that organize these program members into focused translational teams, leading to multi-PI grants and an exceptional rate of intra-programmatic publications; 3) a gynecologic oncology clinical program that impacts the catchment area by providing multidisciplinary care and access to clinical trials (58% enrollment rate) for half the new GC cases in Oklahoma; 4) a large annotated biospecimen bank that supports GC discovery research; 5) active development of GC-focused investigator-initiated trials and high accrual of GC patients to early-phase novel treatment trials; and 6) national leadership in the design and conduct of practice-changing NCTN- and Industry-sponsored randomized GC trials. The GC program has 18 members, representing seven departments, four colleges and two institutions, which illustrates the transdisciplinary expertise among program members. The translational focus of the program is reflected in the balance of MD (9) and PhD (9) members. As of December 31, 2016, program members were awarded $3,865,290 in annual NCI and other peer-reviewed cancer-related support (direct cost). NCI funding ($3,181,558) accounts for 82.3% of the peer-reviewed funding, highlighting the program's cancer focus. Total annual GC program funding is $8,700,601 (direct cost). For the five-year reporting period (2012-2016), GC program members published 262 peer-reviewed articles, of which 34.4% included intra-programmatic, 11.8% included inter-programmatic, and 73.3% included inter-institutional collaborators. For 2016, inter-programmatic publications were 21.1%, highlighting the increasing number of collaborations underway with the Preclinical Translational Cancer Research (PTCR) and Cancer Prevention and Control (CPC) programs.

妇科癌症计划 – 摘要史蒂芬森癌症中心 (SCC) 妇科癌症 (GC) 项目的目标是提高护理标准并改善所有患有妇科恶性肿瘤的女性的临床结果重点解决与俄克拉荷马州（SCC 计划成员）相关的问题。通过进行跨学科、基于团队的研究来实现这一目标，以促进发现 GC 计划的具体目标。是：（1）发现和探究致癌的核心分子机制；（2）研究癌症治疗反应和耐药性的机制；(3) 设计和进行早期和后期随机临床试验可推进新发现并改善患者预后流域地区和国家。 GC计划的亮点包括：1）高度互动的基础发现和临床成员专注于 2) 将这些计划成员组织成有针对性的转化团队的具体目标，导致多项 PI 资助和极高的项目内出版物率；3) 妇科肿瘤学临床计划通过提供多学科护理和获得服务来影响服务区域俄克拉荷马州一半新 GC 病例的临床试验（58% 入组率）4) 大型带注释的生物样本；支持 GC 发现研究的银行；5) 积极开展以 GC 为重点的研究者发起的试验； GC 患者参与早期新治疗试验的比例很高；6) 设计处于国家领先地位；进行改变实践的 NCTN 和行业赞助的随机 GC 试验。 GC计划有18名成员，分别代表七个院系、四个学院和两个机构，说明了项目成员的跨学科专业知识。该项目的转化重点是。截至 2016 年 12 月 31 日，项目成员人数为 MD (9) 和 Ph.D (9)。授予年度 NCI 和其他经过同行评审的癌症相关支持 3,865,290 美元（直接费用）。（3,181,558 美元）占同行评审资金的 82.3%，凸显了该项目对癌症的总体关注。年度 GC 计划资金为 8,700,601 美元（直接费用）五年报告期（2012-2016），GC。项目成员发表了 262 篇同行评审文章，其中 34.4% 包括项目内文章，11.8% 包括项目间合作，2016 年，73.3% 包括机构间合作者。出版物占 21.1%，突显与临床前研究正在进行的合作数量不断增加转化癌症研究 (PTCR) 和癌症预防和控制 (CPC) 计划。